SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+24.18%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$840M
AUM Growth
+$840M
(+39%)
Cap. Flow
+$94.3M
Cap. Flow
% of AUM
11.22%
Top 10 Holdings %
Top 10 Hldgs %
49.44%
Holding
116
New
35
Increased
16
Reduced
23
Closed
30
Top Buys
| 1 |
AbbVie
ABBV
|
$55.9M |
| 2 |
Nice
NICE
|
$24.5M |
| 3 |
Amgen
AMGN
|
$18.9M |
| 4 |
AstraZeneca
AZN
|
$16.9M |
| 5 |
Eli Lilly
LLY
|
$14.8M |
Top Sells
| 1 |
Larimar Therapeutics
LRMR
|
$35.5M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$22.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
$21.6M |
| 4 |
Pfizer
PFE
|
$18M |
| 5 |
Novo Nordisk
NVO
|
$11.5M |
Sector Composition
| 1 | Healthcare | 81.38% |
| 2 | Technology | 10.39% |
| 3 | Consumer Discretionary | 2.06% |
| 4 | Industrials | 1.78% |
| 5 | Communication Services | 1.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $72.1M | 6.78% | 734,598 +569,598 | +345% | +$55.9M |
|
2
Merck
MRK
$210B
| $60.6M | 5.7% | 783,808 -84,710 | -10% | -$6.55M |
|
3
Sanofi
SNY
$121B
| $57.2M | 5.38% | 1,120,000 +150,000 | +15% | +$7.66M |
|
|
4
AstraZeneca
AZN
$248B
| $47.1M | 4.43% | 890,000 +320,000 | +56% | +$16.9M |
|
5
Johnson & Johnson
JNJ
$427B
| $42.2M | 3.97% | 300,000 -48,653 | -14% | -$6.84M |
|
6
Bristol-Myers Squibb
BMY
$96B
| $41.2M | 3.87% | 700,000 -80,000 | -10% | -$4.7M |
|
|
7
Novo Nordisk
NVO
$251B
| $26.2M | 2.46% | 400,000 -176,000 | -31% | -$11.5M |
|
8
Amicus Therapeutics
FOLD
$2.34B
| $24.6M | 2.31% | 1,628,550 -389,074 | -19% | -$5.87M |
|
|
9
Nice
NICE
$8.73B
| $24.5M | 2.3% | +129,406 | New | +$24.5M |
|
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $19.8M | 1.86% | 123,200 -134,800 | -52% | -$21.6M |
|
|
11
Amgen
AMGN
$155B
| $18.9M | 1.77% | +80,000 | New | +$18.9M |
|
|
DCPH
12
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $16.9M | 1.59% | 282,965 +163,465 | +137% | +$9.76M |
|
13
Microsoft
MSFT
$3.77T
| $16.7M | 1.57% | 81,964 -12,000 | -13% | -$2.44M |
|
14
Novartis
NVS
$245B
| $15.7M | 1.48% | 180,000 +40,000 | +29% | +$3.49M |
|
|
15
Eli Lilly
LLY
$657B
| $14.8M | 1.39% | +90,000 | New | +$14.8M |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.8M | 1.2% | +82,049 | New | +$12.8M |
|
17
Fiverr
FVRR
$870M
| $12.3M | 1.16% | 167,002 +62,163 | +59% | +$4.59M |
|
18
Y-mAbs Therapeutics
YMAB
$388M
| $12.2M | 1.15% | 282,252 -25,127 | -8% | -$1.09M |
|
19
Amazon
AMZN
$2.44T
| $11.9M | 1.12% | 4,320 -950 | -18% | -$2.62M |
|
20
Allot
ALLT
$362M
| $10.1M | 0.95% | 963,456 +48,154 | +5% | +$504K |
|
21
Q32 Bio
QTTB
$20.9M
| $10M | 0.94% | +658,919 | New | +$10M |
|
|
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $9.66M | 0.91% | +100,000 | New | +$9.66M |
|
23
WIX.com
WIX
$7.85B
| $9.63M | 0.91% | +37,588 | New | +$9.63M |
|
24
Iovance Biotherapeutics
IOVA
$807M
| $9.55M | 0.9% | +348,000 | New | +$9.55M |
|
|
TRIL
25
DELISTED
Trillium Therapeutics Inc.
TRIL
| $9.53M | 0.9% | 1,178,346 -82,348 | -7% | -$666K |
|